Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26".
Press Release Jan 30 2026
Earlier from Strides Pharma Science
- Press Release Oct 31 2025
- Strides Pharma Science: Intimation on Board Meeting scheduled for Oct 31, 2025
- Press Release Oct 17 2025